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KEY POINTS 
• Induction therapy with CRD improved PFS and OS compared with CTD in transplant-
eligible patients with newly diagnosed multiple myeloma. 
• The best results were achieved when patients received CRD induction therapy and 
lenalidomide maintenance post-ASCT. 
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ABSTRACT  
The optimal way to use immunomodulatory drugs as components of induction and 
maintenance therapy for multiple myeloma is unresolved. We addressed this question in a 
large phase III randomized trial, Myeloma XI. Patients with newly diagnosed multiple 
myeloma (n = 2042) were randomized to induction therapy with cyclophosphamide, 
thalidomide, and dexamethasone (CTD) or cyclophosphamide, lenalidomide, and 
dexamethasone (CRD). Additional intensification therapy with cyclophosphamide, 
bortezomib, and dexamethasone (CVD) was administered before ASCT to patients with a 
suboptimal response to induction therapy using a response-adapted approach. After 
receiving high-dose melphalan with autologous stem cell transplantation (ASCT), eligible 
patients were further randomized to receive either lenalidomide alone or observation alone. 
Co-primary endpoints were progression-free survival (PFS) and overall survival (OS). The 
CRD regimen was associated with significantly longer PFS (median: 36 vs. 33 months; 
hazard ratio [HR], 0.85; 95% confidence interval [CI], 0.75-0.96; P = 0.0116) and OS (3-year 
OS: 82.9% vs. 77.0%; HR, 0.77; 95% CI, 0.63-0.93; P = 0.0072) compared with CTD. The 
PFS and OS results favored CRD over CTD across all subgroups, including patients with 
International Staging System stage III disease (HR for PFS, 0.73; 95% CI, 0.58-0.93; HR for 
OS, 0.78; 95% CI, 0.56-1.09), high-risk cytogenetics (HR for PFS, 0.60; 95% CI, 0.43-0.84; 
HR for OS, 0.70; 95% CI, 0.42-1.15) and ultra high-risk cytogenetics (HR for PFS, 0.67; 95% 
CI, 0.41-1.11; HR for OS, 0.65; 95% CI, 0.34-1.25). Among patients randomized to 
lenalidomide maintenance (n = 451) or observation (n = 377), maintenance therapy 
improved PFS (median: 50 vs. 28 months; HR, 0.47; 95% CI, 0.37-0.60; P < 0.0001). 
Optimal results for PFS and OS were achieved in the patients who received CRD induction 
and lenalidomide maintenance. The trial was registered with the EU Clinical Trials Register 
(EudraCT 2009-010956-93) and ISRCTN49407852. 
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Introduction  
The introduction of novel agents, such as immunomodulatory drugs (IMiDs) and 
proteasome inhibitors, has contributed to the recent dramatic improvements in outcomes 
observed for patients with multiple myeloma.(1-3) Following induction, high-dose melphalan-
based chemotherapy with autologous stem cell transplantation (ASCT) remains the standard 
of care for eligible patients.(4-9) The optimal approach to induction therapy prior to ASCT 
and consolidation or maintenance after ASCT in this new era has not yet been defined. 
However, several principles have been established, including the value of using at least 
triplet combinations of agents that can induce deeper, longer remissions by targeting 
different clonal populations.(10, 11) 
The efficacy of IMiDs in multiple myeloma has been linked to their mode of action. 
These drugs target the cereblon ubiquitin ligase complex, which leads to both tumoricidal 
effects early on and immunomodulatory effects beneficial for long-term tumor control.(12-15) 
The IMiDs thalidomide and lenalidomide are recognized as effective treatment options in 
both the induction (7, 9, 10, 16-18) and maintenance settings.(6, 19-21) Lenalidomide has 
fewer side effects than thalidomide, enabling long-term treatment and disease control.19-21 
We have addressed how to optimize the use of these agents between induction and 
maintenance for patients receiving ASCT in a large, randomized trial (UK National Cancer 
Research Institute [NCRI] Myeloma XI).  
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Methods 
The Myeloma XI study had a multifactorial design enabling the investigation of a 
number of pertinent clinical questions with adequate statistical control and power.  
Importantly, the influence of one phase of treatment or question on another could be 
separated and controlled for. This was achieved by stratifying the consolidation and 
maintenance randomizations for earlier treatment allocations. This report concentrates on 
induction and its interaction with maintenance therapy in the transplant eligible population of 
patients within the trial. The other questions posed by the study are addressed in separate 
manuscripts. 
Study design and eligibility criteria 
The Myeloma XI trial was a phase III, open-label, parallel-group, multi-arm, adaptive 
design trial with 3 randomization stages conducted at 110 National Health Service hospitals 
in England, Wales, and Scotland (see Supplementary Data for list of study sites with 
principal investigators and number of patients recruited). Eligible patients were aged ≥18 
years and newly diagnosed with multiple myeloma. Exclusion criteria included previous or 
concurrent malignancies (including myelodysplastic syndromes), grade ≥2 peripheral 
neuropathy, acute renal failure (unresponsive to up to 72 hours of rehydration, characterized 
by creatinine >500 μmol/L or urine output <400 mL/day or requiring dialysis), and active or 
prior hepatitis C infection.  
The trial design included an intensive treatment pathway for transplant-eligible 
patients and a less-intensive treatment pathway for transplant-ineligible patients. Strict age 
limits were deliberately avoided so that fit, older patients could receive intensive therapy and 
ASCT. The decision of treatment pathway was made on an individual patient basis taking 
into account performance status, clinician judgment, and patient preference.  
Transplant-eligible patients were randomized on a 1:1 basis to cyclophosphamide, 
lenalidomide, and dexamethasone (CRD) or cyclophosphamide, thalidomide, and 
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dexamethasone (CTD) (induction randomization), stratified according to certain factors 
(Supplementary Methods). Patients received a minimum of 4 cycles in the absence of 
progressive disease (PD), and treatment continued until maximum response was achieved.  
Additional intensification therapy before ASCT was administered to patients with a 
suboptimal response to induction therapy using a response-adapted approach: patients with 
stable disease (SD) after induction therapy or those with PD at any time during induction 
therapy received a maximum of 8 cycles of cyclophosphamide, bortezomib, and 
dexamethasone (CVD); patients with a minimal response (MR) or partial response (PR) 
were randomized (1:1) to CVD or no CVD. Patients with very good partial response (VGPR) 
or complete response (CR) received no additional therapy before ASCT. The results of the 
intensification randomisation have been published elsewhere.(22) 
Three months after ASCT, eligible patients were randomized to observation or to 
maintenance therapy with lenalidomide alone, or in combination with vorinostat until 
unacceptable toxicity or PD. Patients were excluded from maintenance randomization if they 
did not respond to CRD induction, had no response to any prior study treatment, had PD, or 
relapsed after achieving CR. Randomized patients were stratified according to treatment 
center and previous randomization group(s). The results of the maintenance randomization 
have been published elsewhere.(23)  
Further details on the dose and schedule of all study treatments are provided in 
Supplementary Table 1, and a flow diagram of the CRD and CTD patient groups is shown 
in Supplementary Figure 1.  
The study was approved by the national ethics review board (National Research 
Ethics Service, London, UK), institutional review boards of the participating centres, and the 
competent regulatory authority (Medicines and Healthcare Products Regulatory Agency, 
London, UK). All patients provided written informed consent. The trial was registered with the 
EU Clinical Trials Register (EudraCT number, 2009-010956-93) and ISRCTN49407852.  
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Study endpoints and statistical analysis 
The co-primary endpoints were progression-free survival (PFS) and overall survival 
(OS). Secondary endpoints included PFS Two (PFS2), response, and safety. Further details 
regarding the statistical analysis are provided in the Methods section in the 
Supplementary Data. 
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Results 
Patients 
Between May 26, 2010 and April 20, 2016, 2042 transplant-eligible patients 
underwent induction randomization (Supplementary Figure 1). Baseline characteristics 
were well balanced between the 2 treatment groups (Table 1). Overall, the median patient 
age was 61 years (range, 28-75 years), 60% of patients were male, and 24% had 
International Staging System (ISS) stage III disease. Of the 836 (40.9%) patients for whom 
genetic risk could be calculated, 266 (31.8%) had high-risk and 111 (13.3%) had ultra-high-
risk cytogenetics. The median follow-up duration from study entry was 36.3 months 
(interquartile range [IQR], 23.0-48.5 months). 
Induction randomization results 
PFS and OS  
Disease progression or death occurred in 456 patients in the CRD group and in 509 
patients in the CTD group. The CRD regimen was associated with significantly longer PFS 
than the CTD regimen (hazard ratio [HR], 0.85; 95% confidence interval [CI], 0.75-0.96; P = 
0.0116; Figure 1A). The median PFS was 36 months (95% Cl, 33-39) with CRD and 33 
months (95% CI, 31-35) with CTD. Median overall survival has not yet reached with current 
follow up. Death occurred in 185 patients in the CRD group and in 230 patients in the CTD 
group. There was also a statistically significant difference in OS favoring CRD (HR, 0.77; 
95% CI, 0.63-0.93; P = 0.0072; Figure 1B). The 3-year OS rate was 82.9% (95% Cl, 80.2-
85.7) with CRD and 77.0% (95% CI, 73.9-80.0) with CTD.  
Subgroup analyses indicated that PFS and OS favored CRD over CTD across all 
subgroups (Figure 2). In the subset of patients with ISS stage III disease, CRD was superior 
to CTD for PFS (HR, 0.73; 95% CI, 0.58-0.93) and there was a trend toward improved OS 
(HR, 0.78; 95% CI, 0.56-1.09). In each case, there was no evidence of heterogeneity of 
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treatment effect (PFS: P = 0.2645; OS: P = 0.7606) (Figure 2). Similar results were seen in 
the subgroup of patients with high-risk cytogenetics (HR for PFS, 0.60; 95% CI, 0.43-0.84; 
HR for OS, 0.70; 95% CI, 0.42-1.15) and ultra-high risk cytogenetics (HR for PFS, 0.67; 95% 
CI, 0.41-1.11; P = 0.6164; HR for OS, 0.65; 95% CI, 0.34-1.25; P = 0.8131), with no 
significant heterogeneity of treatment effect observed (Figure 2). 
PFS2, a secondary endpoint, was also analyzed. CRD was associated with 
significantly longer PFS2 than the CTD (hazard ratio [HR], 0.76; 95% confidence interval 
[CI], 0.65-0.90; P = 0.001; Supplemental Figure 2). The median PFS2 was 59 months 
(95% Cl, 55-63) with CRD and 54 months (95% CI, 49-60) with CTD. 
Response 
After induction triplet therapy, the proportion of patients with VGPR or better was 
significantly higher with CRD compared with CTD (60.4% vs. 52.9%; P = 0.0006) (Table 2). 
The odds ratio (OR) of 1.37 (95% CI, 1.15-1.65) indicates a 37% increase in the odds of 
achieving a deep remission in the CRD group compared with the CTD group. After ASCT, 
the proportion of patients achieving VGPR or better remained higher in the CRD group than 
in the CTD group, but the difference was not statistically significant (81.5% vs. 76.9%; OR, 
1.25; 95% CI, 0.94-1.66; P = 0.1277) (Table 2).  
Due to the lower induction response rate with CTD compared with CRD, more 
patients underwent CVD intensification as per protocol (CRD, 11.8% vs. CTD, 13.3%). The 
interaction between induction therapy and CVD was therefore examined further. 
Counterfactual estimates of the survivor function if CVD rescue treatment was not received 
by any patients maintained differences in median PFS (CRD: 36 months [95% CI, 33-39] vs. 
CTD: 33 months [95% CI, 30-34]); Supplemental Figure 3A) and 3-year OS rate (CRD: 
82.9% [95% CI, 80.0-85.5] vs. CTD: 76.3% [95% CI, 73.0-79.2]; Supplemental Figure 3B). 
Similar counterfactual estimates obtained in the scenario where patients randomized to no 
CVD after PR/MR were treated with CVD provided similar estimates for median PFS (CRD: 
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36 months [95% CI, 33-39] vs. CTD: 33 months [95% CI, 31-36]); Supplemental Figure 3C) 
and 3-year OS rate (CRD: 83.1% [95% CI, 80.2-85.6] vs. CTD: 77.3% [95% CI, 74.1-80.2]; 
Supplemental Figure 3D). After adjustment for the effect of CVD treatment in a 
counterfactual analysis, the hazard ratios for PFS and OS were 0.82 (95% CI, 0.69-0.96) 
and 0.69 (95% CI, 0.53-0.91), respectively. This suggests a greater treatment effect of CRD 
induction treatment on PFS and particularly OS than apparent with the unadjusted ITT 
analysis (Supplemental Figure 3A and 3B, respectively). Full results of the CVD 
intensification randomization have been presented elsewhere.(22)  
Safety 
The median number of cycles of induction therapy delivered was 5 (range, 1-18) for 
CRD and 5 (range, 1-12) for CTD. The median percentage of minimum protocol-defined 
delivered dose of lenalidomide and thalidomide during induction therapy was 116.7% (IQR, 
96.4-150.0) and 100.0% (IQR, 71.4-128.6), respectively. Lenalidomide dose modifications 
occurred in 391 (38.3%) patients who received CRD induction therapy, and thalidomide dose 
modifications occurred in 751 (73.6%) patients who received CTD induction therapy. The 
rate of discontinuation of induction therapy due to AEs was similar with CRD and CTD (51 
patients [5.0%] and 68 patients [6.7%], respectively). Overall, 64.4% of patients proceeded 
to ASCT following induction +/- intensification. There was no difference in the proportion of 
patients undergoing ASCT between those receiving CTD (63.3%) or CRD (65.5%) induction 
suggesting this was not due to induction related toxicity. The most common reason for not 
proceeding was “Patient not fit/clinicians decision” in 36.1% of cases. 
Differences in the safety profile of CRD and CTD were consistent with the known 
side effects of lenalidomide and thalidomide (Table 3). In general, CRD was associated with 
a higher rate of grade ≥3 neutropenia (22.3% vs. 11.7%) and diarrhea (2.6% vs. 1.0%), 
whereas CTD was associated with a higher rate of grade ≥3 peripheral sensory neuropathy 
(1.5% vs. 0.6%) and constipation (1.9% vs. 0.8%). The incidence of deep vein thrombosis 
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was 5.7% in the CRD group and 4.8% in the CTD group; pulmonary embolism was reported 
in 3.2% and 4.9% of patients, respectively.  
The 3-year cumulative incidence of invasive second primary malignancies (SPM) 
was low and comparable between CRD and CTD (2.9% [95% CI, 1.7-4.1] vs. 1.5% [95% CI, 
0.6-2.4]; HR, 1.60 [95% CI, 0.87-2.93]; P = 0.1311). The SPM incidence rate per 100 
patient-years was 1.2 (95% CI, 0.8-1.7) in the CRD group and 0.9 (95% CI, 0.6-1.3) in the 
CTD group.  
The incidence of serious AEs during induction was similar with CRD and CTD (59.0% 
vs. 57.7%). Infection accounted for nearly half of all serious AEs reported during induction 
(45.2% for CRD vs. 46.4% for CTD). Fatal AEs occurred in 6 patients in the CRD group and 
in 3 patients in the CTD group. Of the 9 patients with grade 5 AEs, 1 had 3 concurrent 
events (renal failure, liver failure, and sepsis), 1 had 2 concurrent events (small bowel 
obstruction and sepsis), and the remaining 7 patients had 1 event each (pneumonia [n = 2]; 
sepsis [n = 2]; collapse/syncope [n = 2]; lower respiratory tract infection [n = 1]; hepatitis 
encephalopathy [n = 1]).  
Interaction of lenalidomide induction and maintenance 
Following ASCT, patients were randomized between maintenance lenalidomide and 
observation, giving us the opportunity to explore the interaction between induction and 
maintenance agents in this setting. Of the 2042 transplant-eligible patients that entered the 
first randomization, 1024 entered the maintenance phase and were randomized to 
lenalidomide alone (n = 451), to lenalidomide plus vorinostat (n = 196, not included in this 
further analysis), or to observation (n = 377). Baseline characteristics of patients undergoing 
maintenance randomization were well balanced between the 2 treatment groups 
(Supplementary Table 2). Approximately half of patients in both the lenalidomide and 
observation groups had received CRD as induction therapy (230 of 451 [51.0%] in the 
lenalidomide group; 190 of 377 [50.4%] in the observation group). Lenalidomide 
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maintenance was associated with significantly longer PFS and OS compared with 
observation in transplant-eligible patients (median: 50 vs. 28 months; HR, 0.47; 95% CI, 
0.37-0.60; P < 0.0001 at a median follow-up duration of 27.2 [IQR, 12.8-42.0] months).  
In a post hoc exploratory analysis, the longest PFS was observed in patients who 
received CRD induction and lenalidomide maintenance. Median PFS in this group was not 
reached, while it was 49 months in those who received CTD and lenalidomide maintenance, 
32 months in those who received CTD and observation, and 24 months in those who 
received CRD and observation (Figure 3A). Similarly, the longest OS was observed in 
patients who received CRD induction and lenalidomide maintenance. The median OS was 
not reached in any group, but 3-year OS rates were 92.3% for those who received CRD 
induction with lenalidomide maintenance, 89.0% in those who received CTD and 
lenalidomide maintenance, 86.0% in those who received CTD and observation, and 90.3% 
in those who received CRD and observation (Figure 3B).  
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Discussion  
This is the largest study to evaluate the CRD regimen as induction therapy before 
ASCT in patients with multiple myeloma. We show that it is associated with excellent efficacy 
and safety data and the results are consistent with prior studies evaluating either CTD,(17, 
18, 24)  CRD as induction therapy,(25) or CRD as treatment in the relapsed/refractory 
disease setting.(26)  
A direct comparison of thalidomide and lenalidomide as the immunomodulatory agent 
component of induction therapy has not been previously undertaken in the context of a 
randomized trial for transplant eligible newly diagnosed myeloma patients. Our results 
demonstrate the superiority of lenalidomide over thalidomide both in terms of efficacy and 
tolerability in the context of combination with an alkylating agent (cyclophosphamide), 
supporting the findings of previous non-randomised analyses.(27, 28) Previous randomized 
studies in patients not eligible for stem cell transplant have compared thalidomide to 
lenalidomide in combination with the alkylating agent melphalan.(29, 30) In these studies no 
difference between lenalidomide and thalidomide in terms of response, progression-free or 
overall survival was identified. The differences between these prior studies and the finding 
from Myeloma XI might be explained by the different patient population or the different 
alkylating agent, cyclophosphamide, which may be better tolerated than melphalan. 
Response rates obtained with CRD in the current study were good: 60% of patients 
achieved at least a VGPR after induction and 82% did so post ASCT. This compares 
favorably with other novel-agent-based triplet induction therapies, including bortezomib, 
doxorubicin, and dexamethasone (VAD), (31, 32) CVD,(32) bortezomib, thalidomide, and 
dexamethasone (VTD),(5, 10, 33, 34) and even the IMiD/proteasome inhibitor regimen 
bortezomib, lenalidomide, and dexamethasone (VRD) (9, 35)  (Supplementary Table 3). 
However there are many caveats to trying to compare results across trials. Particularly in 
comparing response rates it should be noted that patients in Myeloma XI received induction 
until maximum response rather than for a fixed duration and this may have led to deeper 
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responses prior to transplant than in other studies. Although immunomodulatory drug and 
proteasome inhibitor combinations (e.g. VTD/VRD) have more recently become widely used 
in the EU and USA this was not the position when the study was initially implemented. At 
that time either an immunomodulatory based regimen or a proteasome inhibitor based 
regimen (e.g. MPV or VD) was used. The standard of care in the UK, as in a number of other 
countries, was CTD.  The addition of a proteasome inhibitor to induction regimens offers the 
potential to target immunomodulatory agent resistant subclones of disease with a second 
novel agent. This concept was explored in the intensification randomisation aspect of the 
study which has been previously reported (22) and demonstrated that intensification 
treatment with CVD significantly improved progression-free survival in patients with newly 
diagnosed multiple myeloma and a suboptimal response to immunomodulatory induction 
therapy compared with no intensification treatment.  
The combination of a fourth agent with a different mechanism of action to induction, 
such as Daratumumab plus VTD (Dara-VTD) in the recently published Cassiopeia trial, is 
able to induce even deeper responses, with 83% of patients achieving at least VGPR.(36)  
PFS with Dara-VTD was prolonged compared to VTD alone, suggesting the addition of 
further agents to active triplets can improve outcomes yet further. In contrast, however, CRD 
offers an all oral regimen requiring only one hospital visit per month and including only one 
more expensive agent, lenalidomide. As such it is comparatively easier to deliver and likely 
to be cheaper in terms of both drug and administration costs. The lower incidence of 
peripheral neuropathy seen with CRD than that seen with combinations including bortezomib 
and/or thalidomide may also be beneficial for some patients.  
The Myeloma XI data support the continued use of ASCT, since in a previous study 
of CRD without ASCT,(7) the median PFS was 28.6 months, which is lower than that 
achieved with CRD and ASCT in the Myeloma XI trial (36 months). Similarly, in the IFM 2009 
study comparing VRD with or without ASCT, the combination of VRD and ASCT led to 
significantly better PFS than VRD alone (median: 50 vs. 36 months; P < 0.001).(9) Median 
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OS in that study was similar in both groups, likely due to the fact that 79% of patients 
assigned to VRD alone received salvage ASCT at relapse and the short current follow up. 
These findings and data from several other studies suggest a complementary role for novel 
agents and ASCT. 
We have shown that treatment with lenalidomide maintenance therapy after ASCT is 
associated with improved PFS and OS, a finding consistent with other reports.(6, 19, 20, 37) 
We show that in Myeloma XI, the efficacy of lenalidomide maintenance was not diminished 
by prior exposure to lenalidomide; in fact, the best outcomes were achieved when 
lenalidomide was given as both induction and maintenance. This is similar to results seen in 
previous lenalidomide maintenance studies, which showed significant heterogeneity of effect 
of lenalidomide maintenance with outcomes favoring those who had received lenalidomide 
induction.(20, 38) This suggests that patients with disease sensitive to immunomodulation 
with lenalidomide will continue to benefit from its continued use, perhaps as the maintenance 
therapy targets quiescent cells as they come out of cycle. 
We noted that patients receiving CRD+obs appeared to have slightly inferior PFS 
than patients receiving CTD+obs. This was not due to any apparent difference in early 
discontinuation of therapy or dose modifications and so is difficult to explain. The PFS 
difference is small, not statistically significant and may have occurred by chance. In the 
analysis of OS the reverse pattern was seen with patients receiving CRD+obs having an 
apparent improved overall survival compared to CTD+obs. 
The results of Myeloma XI are likely to be reflective of the true impact of the CRD 
combination in clinical practice because of the limited exclusion criteria for the study 
population. Notably, there were no age restrictions for the intensive pathway, allowing older 
but fit patients to receive ASCT. The median age in this group was 61 years, and patients up 
to age 75 years were included. In contrast, most previous studies of ASCT have excluded 
patients aged over 65 or 70 years. Evidence suggests that fit patients aged >65 years can 
15 
 
 
benefit from ASCT, especially when combined with regimens containing novel agents.(3, 39, 
40) Our approach may also explain the relatively lower proportion of patients proceeding to 
ASCT in this study than in other studies of induction therapy which are usually limited only to 
patients under the age of 65. The most common reason for patients not proceeding to stem 
cell transplant was given as “patient not fit/clinicians decision” suggesting that clinicians may 
have initially entered patients in the transplant eligible pathway of the study as a ‘trial of 
fitness’ so as not to limit their options prior to withdrawing the patient nearer the time of 
transplant.   
In addition, the proportion of patients with ISS stage III disease (24%) in the present 
study was slightly higher than that in some recent studies of induction therapy.(9, 10, 31, 35) 
Cytogenetic abnormalities, such as t(4;14), t(14;16), and del(17p), are important prognostic 
markers, and should therefore be investigated in all patients with multiple myeloma 
according to the International Myeloma Working Group (IMWG) molecular 
classification.(41) Although cytogenetic data were only available for 41% of patients in our 
study, this percentage is comparable to that in other trials of patients with newly 
diagnosed multiple myeloma.(42) 
While 3-drug induction regimens are generally more effective than 2-drug regimens, 
they may also be more toxic.(10, 11) In the Myeloma XI trial, the safety results for CRD and 
CTD were consistent with the known safety profiles of these agents. Notably, rates of 
peripheral neuropathy were lower with CRD than with CTD. An important safety concern with 
lenalidomide treatment in patients with newly diagnosed multiple myeloma is the risk of 
SPM.(43) In this population of transplant-eligible patients, the overall 3-year cumulative 
incidence of invasive SPM was low (2.2%; 95% CI, 1.5-3.0) and the type of induction therapy 
used did not appear to affect the SPM incidence rate. Safety results for lenalidomide 
maintenance compared to observation including SPM incidence have been previously 
published.(23, 44) Despite the risks associated with continued active therapy, registry data 
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suggest that health-related quality of life of patients receiving lenalidomide maintenance is 
similar to that of patients receiving no maintenance.(45)  
In summary, induction therapy with CRD improved PFS and OS compared with CTD 
in transplant-eligible patients with newly diagnosed multiple myeloma. The best results were 
achieved when patients received both lenalidomide-based induction therapy and 
lenalidomide maintenance.  
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Table 1. Patient characteristics according to induction regimen 
Characteristic CRD (n = 1021) CTD (n = 1021) 
Median age (range), years 61 (28-75) 61 (29-74) 
Age group, n (%)   
≤65 years 772 (75.6) 754 (73.8) 
>65 years 249 (24.4) 267 (26.2) 
Sex, n (%)   
Male 610 (59.7) 611 (59.8) 
Female 411 (40.3) 410 (40.2) 
Ethnicity, n (%)   
White  938 (91.9) 937 (91.8) 
Black (Black Caribbean, Black African, other) 21 (2.1) 14 (1.4) 
Asian (Indian, Pakistani, Bangladeshi, other) 28 (2.7) 27 (2.6) 
Other 10 (0.9) 14 (1.4) 
Unknown 24 (2.4) 29 (2.8) 
WHO performance status, n (%)   
0 421 (41.2) 439 (43.0) 
1 363 (35.6) 367 (35.9) 
2 119 (11.7) 135 (13.2) 
≥3 53 (5.2) 34 (3.3) 
Unknown 65 (6.4) 46 (4.5) 
Immunoglobin subtype, n (%)   
IgG 633 (62.0) 600 (58.8) 
IgA 220 (21.5) 269 (26.3) 
IgM 4 (0.4) 4 (0.4) 
IgD 12 (1.2) 9 (0.9) 
Light chain only 139 (13.6) 127 (12.4) 
Non-secretor 6 (0.6) 7 (0.7) 
Unknown 7 (0.7) 5 (0.5) 
ISS stage, n (%)   
I 301 (29.5) 306 (30.0) 
II 392 (38.4) 388 (38.0) 
III 246 (24.1) 253 (24.8) 
Unknown 82 (8.0) 74 (7.2) 
Median serum creatinine (range), μmol/L 85.0 (28.0-825.0) 83.0 (30.0-897.0) 
Unknown, n (%) 9 (8.8) 7 (6.9) 
Median lactate dehydrogenase (range), IU/L 262.0 (3.0-2519.0) 273.0 (0.0-3550.0) 
Unknown, n (%) 228 (22.3) 215 (21.1) 
CVD randomization after MR/PR, n (%)   
Allocated to CVD 85 (8.3) 98 (9.6) 
Allocated to no CVD 82 (8.0) 102 (10.0) 
Received CVD after SD/PD, n (%) 35 (3.4) 38 (3.7) 
Maintenance treatment, n (%)   
Lenalidomide  230 (22.5) 221 (21.6) 
Lenalidomide plus vorinostat  103 (10.1) 93 (9.1) 
Observation 190 (18.6) 187 (18.3) 
Cytogenetic data available, n (%) 414 (40.5) 422 (41.3) 
Cytogenetic lesions, n (% of those with data available) 
t(4;14) 56 (13.5) 70 (16.6) 
t(14;16) 8 (1.9) 12 (2.8) 
t(14;20) 3 (0.7) 2 (0.5) 
del(17p) 31 (7.5) 42 (10.0) 
gain(1q) 137 (33.1) 136 (32.2) 
Cytogenetic risk category, n (% of those with data available) 
Standard 223 (53.9) 236 (55.9) 
High* 149 (36.0) 117 (27.7) 
Ultra-high† 42 (10.1) 69 (16.4) 
Abbreviations: CRD, cyclophosphamide, lenalidomide, and dexamethasone; CTD, cyclophosphamide, 
thalidomide, and dexamethasone; CVD, cyclophosphamide, bortezomib, and dexamethasone; Ig, 
immunoglobulin; ISS, International Staging System; MR, minimal response; PD, progressive disease; PR, partial 
response; SD, stable disease; WHO, World Health Organization. *High risk defined as the presence of any one of 
t(4;14), t(14;16), t(14;20), del(17p), or gain(1q). †Ultra-high risk defined as the presence of more than 1 lesion. 
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Table 2. Response rates after induction and ASCT  
 Response following induction 
therapy 
Response following  
ASCT 
Response, n (%) CRD  
(n = 1021) 
CTD  
(n = 1021) 
CRD  
(n = 628) 
CTD  
(n = 603) 
CR or VGPR 617 (60.4) 540 (52.9) 512 (81.5) 464 (76.9) 
 CR 87 (8.5) 61 (6.0) 149 (23.7) 122 (20.2) 
 CR w/o BM 297 (29.1) 223 (21.8) 218 (34.7) 214 (35.5) 
 VGPR 233 (22.8) 256 (25.1) 145 (23.1) 128 (21.2) 
PR or MR 297 (29.1) 348 (34.1) 95 (15.1) 102 (16.9) 
 PR 261 (25.6) 301 (29.5) 94 (15.0) 98 (16.3) 
 MR 36 (3.5) 47 (4.6) 1 (0.2) 4 (0.7) 
SD or PD 32 (3.1) 43 (4.2) 11 (1.8) 10 (1.7) 
 SD 8 (0.8) 8 (0.8) 0 (0.0) 0 (0.0) 
 PD 24 (2.4) 35 (3.4) 11 (1.8) 10 (1.7) 
Death within 100 
days after ASCT 
13 (1.3) 17 (1.7) 1 (0.2) 6 (1.0) 
Unknown 57 (5.6) 61 (6.0) 9 (0.9) 21 (2.1) 
Abbreviations: ASCT, autologous stem cell transplantation; CR, complete response; CR w/o BM, complete 
response by immunological criteria without confirmation by bone marrow; CRD, cyclophosphamide, lenalidomide, 
and dexamethasone; CTD, cyclophosphamide, thalidomide, and dexamethasone; MR, minimal response; PD, 
progressive disease; PR, partial response; SD, stable disease; VGPR, very good partial response.  
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Table 3. Adverse events according to induction regimen (safety population*) 
Grade ≥3 AEs, n (%) CRD  
(n = 1010) 
CTD  
(n = 1004) 
Neutropenia 225 (22.3) 117 (11.7) 
Anemia 97 (9.6) 67 (6.7) 
Thrombocytopenia 46 (4.5) 17 (1.7) 
Diarrhea 26 (2.6) 10 (1.0) 
Constipation 8 (0.8) 19 (1.9) 
Peripheral sensory neuropathy 6 (0.6) 15 (1.5) 
Peripheral motor neuropathy 5 (0.5) 14 (1.4) 
AEs of interest  
(any grade), n (%) 
CRD  
(n = 1010) 
CTD  
(n = 1004) 
Peripheral sensory neuropathy 251 (24.9) 452 (45.0) 
Peripheral motor neuropathy 87 (8.6) 163 (16.2) 
Deep vein thrombosis  58 (5.7) 48 (4.8) 
Pulmonary embolism  32 (3.2) 49 (4.9) 
Other thrombosis/embolism  8 (0.8)  11 (1.1) 
Abbreviations: AE, adverse event; CRD, cyclophosphamide, lenalidomide, and dexamethasone; CTD, 
cyclophosphamide, thalidomide, and dexamethasone. 
*The safety population included all randomly assigned patients who received 1 or more doses of the induction or 
maintenance regimen. 
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Figure Legends: 
Figure 1. Outcomes according to induction regimen. (A) Progression-free survival and 
(B) overall survival, with dashed line showing the median. Abbreviations: CRD, 
cyclophosphamide, lenalidomide, and dexamethasone; CTD, cyclophosphamide, 
thalidomide, and dexamethasone. 
Figure 2. Outcomes according to induction regimen in selected subgroups. (A) 
Progression-free survival and (B) overall survival; HR < 1.00 favors CRD. *Likelihood ratio 
test for heterogeneity of effect amongst patients with subgroup data available. Abbreviations: 
CI, confidence interval; CRD, cyclophosphamide, lenalidomide, and dexamethasone; CTD, 
cyclophosphamide, thalidomide, and dexamethasone; het, heterogeneity; HiR, high risk; HR, 
hazard ratio; ISS, International Staging System; SR, standard risk; UHiR, ultra-high risk. 
Figure 3. Outcomes according to induction and maintenance treatment. (A) 
Progression-free survival and (B) overall survival. Abbreviations: CRD, cyclophosphamide, 
lenalidomide, and dexamethasone; CTD, cyclophosphamide, thalidomide, and 
dexamethasone; Obs, observation; R, lenalidomide. 
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SUPPLEMENTARY DATA 
Supplemental Methods 
Supportive care recommendations 
For all patients, bisphosphonates were recommended until PD and thromboprophylaxis was 
recommended for at least the first 3 months of treatment as per International Myeloma 
Working Group (IMWG) recommendations. Growth factor support and prophylaxis for 
pneumonia varicella, fungal infection, and tumor lysis syndrome were allowed as per local 
practice. All patients provided written informed consent.  
Stratification Factors 
Transplant-eligible patients were randomized on a 1:1 basis stratified according to the 
following minimization factors: treatment center, β2-microglobulin level (<3.5 mg/L, 3.5-5.5 
mg/L, ≥5.5 mg/L, or unknown), hemoglobin level (<11.5 vs. ≥11.5 g/dL for men; <9.5 vs. ≥9.5 
g/dL for women), corrected serum calcium level (<2.6 vs. ≥2.6 mmol/L), serum creatinine level 
(<140 vs. ≥140 µmol/L), and platelet count (<150 × 109/L vs. ≥150 × 109/L). 
Cytogenetic analysis 
Cytogenetic profiling was performed using Multiplex Ligation-dependent Probe 
Amplification (MLPA) and quantitative real-time PCR (qRT-PCR) on samples of CD138-
selected plasma cells from bone marrow biopsies of patients. These techniques have been 
previously validated to provide equivalent results to interphase fluorescence in situ 
hybridization (iFISH).1,2 Cytogenetic risk was defined as standard risk (no adverse lesions), 
high risk (presence of gain(1q), t(4;14), t(14;16), t(14;20), or del(17p)), or ultra-high risk (more 
than 1 adverse lesion).3  
Randomization 
All randomizations were performed at the Clinical Trials Research Unit (Leeds, UK) 
using a centralized automated 24-hour telephone system according to a validated 
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minimization algorithm. Due to the nature of the intervention, patients and their physicians 
were aware of the treatment allocation.  
Study endpoint definitions 
For induction therapy comparisons, PFS was defined as the time from induction 
randomization to the date of confirmed disease progression or death from any cause. OS was 
defined as the time from induction randomization to the date of death from any cause. PFS2 
was defined as the time from induction randomization to the date of second disease 
progression (or start of third anti-myeloma treatment), or death from any cause. For 
maintenance therapy comparisons, PFS and OS were defined similarly as the time from 
maintenance randomization. Disease progression and response were defined based on the 
Modified International Uniform Response Criteria 4,5 and reviewed centrally by an expert panel 
that was blinded to treatment allocation. Adverse event (AE) severity was graded according 
to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. The intent-to-
treat population included all randomly assigned patients and was used to assess efficacy. The 
safety population included all randomly assigned patients who received 1 or more doses of 
study medication. The data-cutoff date for inclusion in this analysis was July 25, 2016. 
Statistical analysis 
Statistical analyses were undertaken in SAS (version 9.4; SAS Institute, Cary, NC, 
USA), Stata IC (StataCorp, College Station, TX, USA), and R: A Language and Environment 
for Statistical Computing (R Core Team, Vienna, Austria). Analysis followed the Myeloma XI 
statistical analysis plan (SAP) unless reported as post hoc exploratory analysis. Cox 
regression was used to analyze progression-free survival (PFS) and overall survival (OS) and 
estimate hazard ratios (HR) and 95% confidence intervals. All analyses were adjusted for the 
minimization factors (excluding center). The Kaplan-Meier method was used to estimate 
survivor functions. Flexible parametric survival models were used to estimate median survival 
in OS.6 Subgroup analysis was pre-specified for the presence or absence of adverse 
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cytogenetic lesions. Response rates (specifically, remission defined as a very good partial 
response [VGPR] or better, vs. no VGPR) were compared with logistic regression analysis 
adjusted for the minimization factors (excluding center). 
The use of additional therapy (cyclophosphamide, bortezomib, and dexamethasone 
[CVD]) for patients with a suboptimal response (ie, minimal response [MR] or partial response 
[PR]) or no response (ie, stable disease [SD] or progressive disease [PD]) after induction 
therapy was a potential source of bias in the comparison of outcomes associated with 
cyclophosphamide, lenalidomide, and dexamethasone (CRD) and cyclophosphamide, 
thalidomide, and dexamethasone (CTD) (ie, a lower response rate in one treatment group 
could lead to more patients being ‘rescued’ with CVD). Post hoc exploratory analysis 
considered rank-preserving structural failure time models relating the observed PFS and OS, 
to the counterfactual estimates observable without subsequent treatment with CVD after 
suboptimal or no response.7-9 
 The percentage of minimum protocol-defined dose delivered for induction therapy was 
calculated as the sum of the study drug doses delivered to a patient out of the total dose 
expected to be delivered for the protocol-defined minimum of 4 cycles in the absence of PD. 
The percentage of maximum protocol-defined dose delivered for lenalidomide maintenance 
therapy was calculated as the sum of the study drug doses delivered to a patient out of the 
total dose expected to be delivered up to PD. 
Cumulative incidence function curves were estimated by non-parametric maximum 
likelihood estimation.10 Fine and Gray competing risks regression11 was used to compare the 
hazard of second primary malignancies (SPM) by treatment, adjusting for the minimization 
factors with unrelated deaths specified as a competing risk. Person-years on trial were 
calculated as the sum over all patients receiving at least 1 dose of study treatment of the time 
in years from randomization to death or last date known to be alive. Incidence rates were 
calculated with the number of events as the numerator and the number of person-years on 
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trial as the denominator. Confidence intervals for incidence rate were calculated using 
approximations to the Poisson distribution. 
The trial was designed to demonstrate an increase in median OS of 18 months in the 
CRD group (median, 84 months) compared with the CTD group (median, 66 months; HR, 
0.79) when 545 OS events had been observed. This calculation assumed the time-to-event 
was exponentially distributed and that recruitment would last 4 years with 4 years of further 
follow-up, a 2-sided 5% significance level, and 80% power. A minimum recruitment target of 
1183 patients randomized (1:1) between CRD and CTD was specified, allowing for 5% drop-
out. Under similar assumptions, this recruitment also allowed the demonstration of a PFS 
increase of 6 months in the CRD group (median, 35 months) compared with the CTD group 
(median, 29 months; HR, 0.83) when 893 PFS events had been observed. The standard 
therapy estimates were taken from the MRC Myeloma IX trial.12 
A formal interim analysis for OS was pre-specified in the study protocol when at least 
50% of required OS events had been observed (273 deaths). To ensure that an overall 
significance level of 0.05 was maintained, the O’Brien and Fleming alpha-spending function13 
was used with pre-specified bounds of 0.005 for interim analysis and 0.047 for final analysis. 
The bound for the interim analysis was advisory with decision to release results at the 
recommendation of the Independent Myeloma XI Data Monitoring and Ethics Committee 
(DMEC) and Independent Myeloma XI Trial Steering Committee (TSC). On September 1, 
2016, the Myeloma XI DMEC reviewed the interim analysis for OS that showed that the pre-
specified boundary had been achieved based on 407 OS events (74.7% of required OS 
events). Based on the DMEC review, the Myeloma XI TSC recommended that the results be 
unmasked. The results presented in this manuscript were updated based on final cleaned data 
and the addition of 8 late-reported deaths. 
All the authors vouch for the accuracy and completeness of the data and for the adherence of 
the trial to the protocol (study protocol and statistical analysis plan are available upon request). 
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Supplementary Table 1. Study regimens  
CRD 
(cyclophosphamide, 
lenalidomide, 
dexamethasone) 
C: 500 mg po on days 1, 8 
R: 25 mg daily po on days 1-21 
D: 40 mg daily po on days 1-4, 
12-15 
Cycles repeat every 28 days for at 
least 4 cycles and until maximum 
response achieved. 
Patients with PD will proceed directly 
to CVD (without having to complete 4 
cycles of induction) and patients with 
SD after 4 cycles will go straight to 
CVD. 
CTD 
(cyclophosphamide, 
thalidomide, 
dexamethasone) 
C: 500 mg po on days 1, 8, 15 
T: 100 mg daily po for 3 weeks, 
increasing to 200 mg daily po  
D: 40 mg daily po on days 1-4, 
12-15 
Cycles repeat every 21 days for at 
least 4 cycles and until maximum 
response achieved. 
Patients with PD will proceed directly 
to CVD (without having to complete 4 
cycles of induction) and patients with 
SD after 4 cycles will go straight to 
CVD. 
CVD 
(cyclophosphamide, 
bortezomib, 
dexamethasone) 
C: 500 mg daily po on days 1, 8, 
15 
V: 1.3 mg/m2 sc or iv on days 1, 
4, 8, 11 
D: 20 mg daily po on days 1-2, 4-
5, 8-9, 11-12 
Cycles repeat every 21 days until 
maximum response or intolerance 
(maximum 8 cycles). 
If CR is achieved, treatment was 
continued for a maximum of 2 
additional cycles. Varicella 
prophylaxis was recommended as per 
local practice. 
Lenalidomide 
maintenance* 
R: 10 mg daily po on days 1-21 
Cycles repeat every 28 days and 
continue, in the absence of toxicity, 
until disease progression. 
Lenalidomide plus 
vorinostat 
maintenance* 
R: 10 mg daily po on days 1–21 
Vorinostat: 300 mg daily po on 
days 1–7 and 15–21 
Cycles repeat every 28 days and 
continue, in the absence of toxicity, 
until disease progression 
Abbreviations: C, cyclophosphamide; CR, complete response; D, dexamethasone; iv, 
intravenously; PD, progressive disease; po, orally; R, lenalidomide; sc, subcutaneously; SD, 
stable disease; T, thalidomide; V, bortezomib. 
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* Patients were accrued to the maintenance randomization between January 13, 2011 and 
August 11, 2017. Patients were initially randomized in a 1:1 ratio, using minimization with a 
bias element of 80%, to either R 25 mg/day (po on days 1–21 of each 28-day cycle) or 
observation, stratified by induction and intensification treatment. Following a protocol 
amendment on September 14, 2011 and after accrual of 442 patients under protocol versions 
2·0–4·0, patients were randomized in a 1:1:1 ratio to R 10 mg/day (po on days 1–21 of each 
28-day cycle), R plus vorinostat, or observation. Following a further protocol amendment on 
June 28, 2013 and after accrual of 615 further patients under protocol version 5·0, patients 
were randomized in a 2:1 ratio to R 10 mg/day or observation; R plus vorinostat was 
discontinued under protocol version 6·0. These changes were made to add research 
questions to this adaptive design study. Abbreviations: a, attenuated-dose; C, 
cyclophosphamide; CR, complete response; D, dexamethasone; iv, intravenously; PD, 
disease progression; po, orally; R, lenalidomide; sc, subcutaneously; T, thalidomide; V, 
bortezomib. 
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Supplementary Table 2. Baseline characteristics of transplant-eligible patients who 
entered maintenance randomization 
Characteristic 
Lenalidomide  
(n = 451) 
Observation  
(n = 377) 
Induction regimen, n (%)   
CRD 230 (51.0) 190 (50.4) 
CTD 221 (49.0) 187 (49.6) 
CVD randomization after MR/PR, n (%)   
Allocated to CVD 47 (10.4) 37 (9.8) 
Allocated to no CVD 47 (10.4) 40 (10.6) 
Received CVD after SD/PD, n (%) 357 (79.2) 300 (79.6) 
Response status before maintenance, n (%)   
CR 101 (22.4) 85 (22.5) 
VGPR 264 (58.5) 230 (61.0) 
PR 74 (16.4) 53 (14.1) 
MR 2 (0.4) 1 (0.3) 
SD 0 (0.0) 0 (0.0) 
PD 4 (0.9) 3 (0.8) 
Unable to assess 4 (0.9) 3 (0.8) 
Unknown 2 (0.4) 2 (0.5) 
Median age (range), years 61.0 (29.0-75.0) 61.0 (30.0-74.0) 
Sex, n (%)   
Male 294 (65.2) 235 (62.3) 
Female 157 (34.8) 142 (37.7) 
Ethnicity, n (%)   
White  418 (92.7) 350 (92.8) 
Black (Black Caribbean, Black African, other) 6 (1.3) 9 (2.4) 
Asian (Indian, Pakistani, Bangladeshi, other) 6 (1.3) 8 (2.1) 
Other 6 (1.3) 4 (1.1) 
Unknown 15 (3.4) 6 (1.6) 
ISS stage, n (%)   
I 149 (33.0) 137 (36.3) 
II 168 (37.3) 148 (39.3) 
III 97 (21.5) 71 (18.8) 
Unknown 37 (8.2) 21 (5.6) 
Cytogenetic data available, n (%) 178 155 
Cytogenetic lesions, n (% of those with data available) 
t(4;14) 29 (16.3) 17 (11.1) 
t(14;16) 5 (2.8) 5 (3.2) 
t(14;20) 2 (1.1) 0 (0.0) 
del(17p) 17 (9.6) 9 (5.8) 
gain(1q) 69 (38.8) 44 (28.4) 
Cytogenetic risk category, n (% of those with data available) 
Standard 86 (48.3) 97 (62.6) 
High* 66 (37.1) 41 (26.5) 
Ultra-high† 26 (14.6) 17 (11.0) 
Abbreviations: CR, complete response; CRD, cyclophosphamide, lenalidomide, and dexamethasone; 
CTD, cyclophosphamide, thalidomide, and dexamethasone; CVD, cyclophosphamide, bortezomib, and 
dexamethasone; ISS, International Staging System; MR, minimal response; PD, progressive disease; 
PR, partial response; SD, stable disease; VGPR, very good partial response. 
*High risk defined as the presence of any one of t(4;14), t(14;16), t(14;20), del(17p), or gain(1q).  
†Ultra-high risk defined as the presence of more than 1 lesion.  
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Supplementary Table 3. Published randomized studies evaluating 3/4-drug 
combinations of newer agents as induction therapy prior to ASCT  
Induction 
regimen 
Phase N Age 
restriction 
(median), 
years 
ISS 
stage 
III, % 
Response 
after 
induction, % 
Response after 
ASCT, % 
Median 
PFS, 
months 
Median 
OS, 
months 
Reference 
≥PR ≥VGPR ≥PR ≥VGPR 
VAD III 413 ≤65 (57) 20 78 42 88 62 35 5-year: 
61% 
Sonneveld 
et al32 
VAD III 251 ≤70 (59.4) 29 72 34 NR NR NR NR Mai et al33 
CVD III 251 ≤70 (58.7) 30 78 37 NR NR NR NR Mai et al33 
CTD III 555 None (59) 29 83 43 92 74 27 Not 
reached 
Morgan et 
al17 
VTD III 236 ≤65 (58) 16 93 62 93 79 3-year: 
68% 
3-year: 
86% 
Cavo et 
al10 
VTD III 130 ≤65 (56) NR 85 60 NR NR 56.2 4-year: 
74% 
Rosiñol et 
al34 
VTD III 100 ≤65 (58) 23 88 49 89 74 26 NR Moreau et 
al5 
VRD III 350 ≤65 (60) 17 NR 47 NR 78 36 4-year: 
82% 
Attal et al9 
VRD Rand II 42 None (60) 19 85 51 NR NR 1-year: 
83% 
1-year: 
100% 
Kumar et 
al36 
CVRD Rand II 48 None 
(61.5) 
21 80 33 NR NR 1-year: 
86% 
1-year: 
92% 
Kumar et 
al36 
Dara-VTd III 543 ≤65 (59) 15 93 65 93 83 18m: 
93% 
NR Moreau et 
al37 
VTd III 542 ≤65 (58) 15 90 56 90 78 18m: 
85% 
NR Moreau et 
al37 
CTD III 1021 None (61) 25 82 53 93 77 33 64 Myeloma 
XI      
(present 
study) 
CRD III 1021 None (61) 24 86 60 97 82 36 64 Myeloma 
XI      
(present 
study) 
 
Abbreviations: ASCT, autologous stem cell transplantation; CRD, cyclophosphamide, lenalidomide, and 
dexamethasone; CTD, cyclophosphamide, thalidomide, and dexamethasone; CVD, 
cyclophosphamide, bortezomib, and dexamethasone; CVRD, cyclophosphamide, bortezomib, 
lenalidomide, and dexamethasone; CVTD, cyclophosphamide, bortezomib, thalidomide, and 
dexamethasone; ISS, International Staging System; KCD, carfilzomib, cyclophosphamide, and 
dexamethasone; KRD, carfilzomib, lenalidomide, and dexamethasone; NR, not reported; OS, overall 
survival; PFS, progression-free survival; PR, partial response; Rand, randomized; VAD, bortezomib, 
doxorubicin, and dexamethasone; VGPR, very good partial response; VRD, bortezomib, lenalidomide, 
and dexamethasone; VTD, bortezomib, thalidomide, and dexamethasone. 
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Supplementary Figure 1. Patient disposition. Dashed-outline boxes: outcomes for patients assigned to lenalidomide plus vorinostat 
maintenance therapy not included in the present manuscript. *Across the intensive pathway, 34 patients with final response classified as ‘Missing’ 
or ‘Unable to assess’ carried on with trial treatment based on their clinician’s decision. The CONSORT diagram presents the local response 
assessment and may not correspond with the reviewed response as presented in the main text.  
Abbreviations: ASCT, autologous stem cell transplantation; CR, complete response; CRD, cyclophosphamide, lenalidomide, and 
dexamethasone; CTD, cyclophosphamide, thalidomide, and dexamethasone; CVD, cyclophosphamide, bortezomib, and dexamethasone; MR, 
minimal response; PD, progressive disease; PR, partial response; SD, stable disease; VGPR, very good partial response. 
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Supplementary Figure 2. PFS2 according to induction regimen. Abbreviations: CRD, cyclophosphamide, lenalidomide, and 
dexamethasone; CTD, cyclophosphamide, thalidomide, and dexamethasone. 
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Supplementary Figure 3. RPSFTM counterfactual adjusted survivor function for CRD vs. CTD. (A) PFS without treatment rescue 
with CVD, (B) OS without treatment rescue with CVD, (C) PFS with treatment rescue with CVD, and (D) OS with treatment rescue with 
CVD. 
Abbreviations: CI, confidence interval; CRD, cyclophosphamide, lenalidomide, and dexamethasone; CTD, cyclophosphamide, 
thalidomide, and dexamethasone; CVD, cyclophosphamide, bortezomib, and dexamethasone; ITT, intention to treat; OS, overall 
survival; PFS, progression-free survival; RPSFTM, rank-preserving structural failure time model. 
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Study sites, principal investigators, and number of patients recruited 
Site Principal Investigator(s) 
Recruited 
patients 
Leicester Royal Infirmary Dr. Mamta Garg, Dr. Claire Chapman 65 
Nottingham City Hospital Dr. Cathy Williams, Prof. Nigel Russell 60 
Royal Derby Hospital Dr. David Allotey 55 
Royal Stoke University Hospital, Stafford County Hospital (University 
Hospital North Staffordshire) 
Dr. Kamaraj Karunanithi, Dr. Paul Revell 55 
Worcestershire Royal Hospital, Alexandra Hospital Redditch, 
Kidderminster General Hospital 
Dr. Salim Shafeek 54 
Manchester Royal Infirmary, Trafford General Hospital Dr. Alberto Rocci, Dr. Eleni Tholouli, Dr. John 
Alderson, Dr. Simon Gibbs 
52 
Lincoln County Hospital, Grantham and District General Hospital, 
Pilgrim Hospital Boston 
Dr. Caroline Harvey, Dr. Charlotte Kallmeyer, Dr. 
Kandeepan Saravanmuttu 
50 
Birmingham Heartlands Hospital, Good Hope Hospital Dr. Bhuvan Kishore, Prof. Donald Milligan 48 
Royal Hallamshire Hospital, Sheffield Prof. John Snowden 48 
Royal Cornwall Hospital, Truro Dr. Julie Blundell 40 
New Cross Hospital, Wolverhampton Dr. Supratik Basu 36 
University Hospital of Wales Cardiff, Llandough Hospital Dr. Ceri Bygrave, Dr. Christopher Fegan, Dr. 
Belinda Austin 
35 
Doncaster Royal Infirmary Dr. Joe Joseph, Dr. Youssef Sorour 34 
Southmead Hospital, Bristol (Frenchay) Dr. Alastair Whiteway 33 
Western General Hospital, Edinburgh Dr. Huw Roddie 33 
Royal Oldham Hospital Dr. Hayley Greenfield 31 
Southampton General Hospital Dr. Matthew Jenner, Dr. Alastair Smith 31 
The Christie, Manchester Dr. Samar Kulkarni, Dr. Jim Cavet 31 
Cheltenham General Hospital, Gloucestershire Royal Hospital Dr. Sally Chown 30 
Royal Marsden Hospital, London Dr. Martin Kaiser, Prof. Gareth Morgan 30 
Stoke Mandeville Hospital, Wycombe Hospital Dr. Robin Aitchison 30 
Blackpool Victoria Hospital Dr. Mark Grey, Dr. Marian Paul Macheta 29 
Royal Preston Hospital Dr. Mark Grey, Dr. Frederick Kanyike, Dr. Maqsood 
Punekar 
29 
St James's University Hospital, Leeds Prof. Gordon Cook 29 
Freeman Hospital, Newcastle Prof. Graham Jackson 28 
Singleton Hospital, Swansea Dr. Hamdi Sati 28 
Worthing Hospital, St Richards Hospital Chichester Dr. Jamie Wilson, Dr. Sarah Janes, Dr. Phillip 
Bevan, Dr. Santosh Narat 
28 
Derriford Hospital, Plymouth Dr. Hannah Hunter 27 
James Cook University Hospital, Middlesbrough Dr. Raymond Dang 27 
Royal Bournemouth Hospital Dr. Rachel Hall 27 
Medway Maritime Hospital Dr. Sarah Arnott, Dr. Vijay Dhanapal, Dr. Vivienne 
Andrews 
26 
York Hospital, Scarborough General Hospital Dr. Laura Munro, Dr. Haz Sayala 26 
Kent and Canterbury Hospital Dr. Jindriska Lindsay 25 
Stepping Hill Hospital, Stockport Dr. Montaser Haj 25 
Diana Princess of Wales Hospital, Grimsby Dr. Susan Levison-Keating, Dr. Sanjeev Jalihal, Dr. 
Hannah Ciepluch 
24 
Norfolk and Norwich University Hospital Dr. Martin Auger, Dr. Kristian Bowles 24 
Russells Hall Hospital, Dudley Dr. Craig Taylor 24 
Bristol Haematology and Oncology Centre Dr. Jenny Bird, Dr. Roger Evely 23 
Calderdale Royal Hospital, Huddersfield Royal Infirmary Dr. Kate Rothwell, Dr. Sylvia Feyler 23 
Ipswich Hospital Dr. Isobel Chalmers 23 
Royal Berkshire Hospital, Reading Dr. Henri Grech 23 
Chesterfield Royal Hospital Dr. Peter Toth, Dr. Emma Welch 22 
Queen's Hospital, Romford Dr. Sandra Hassan, Dr. Biju Krishnan, Dr. Jane 
Stevens 
22 
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Site Principal Investigator(s) 
Recruited 
patients 
Royal Devon and Exeter Hospital Dr. Tony Todd, Dr. Claudius Rudin 22 
Aberdeen Royal Infirmary Dr. Jane Tighe 21 
Castle Hill Hospital, Hull Dr. David Allsup, Dr. Haz Sayala 21 
Beatson Oncology Centre, Glasgow Dr. Richard Soutar 20 
University Hospital Coventry Dr. Beth Harrison, Dr. Syed Bokhari 20 
Ninewells Hospital Dundee, Perth Royal Infirmary Dr. Duncan Gowans 19 
Sandwell General Hospital, West Bromwich Dr. Farooq Wandroo 18 
Queen Elizabeth Hospital, Birmingham Dr. Mark Cook 17 
Royal Gwent Hospital, Newport Dr. Helen Jackson 17 
Dorset County Hospital Dr. Dietman Hofer, Dr. Akeel Moosa 16 
Kettering General Hospital Dr. Mark Kwan 16 
King's Mill Hospital, Sutton-in-Ashfield Dr. Tim Moorby, Dr. Rowena Faulkner 16 
Salisbury District Hospital Dr. Jonathan Cullis 16 
Victoria Hospital Kirkcaldy Dr. Lorna McClintock 16 
Royal Blackburn Hospital Dr. Malgorzata Rokicka, Dr. Jagdish Adiyodi 15 
Royal Lancaster Infirmary Dr. David Howarth 15 
Colchester General Hospital Dr. Michael Hamblin, Dr. Sudhakaran Makkuni 14 
Eastbourne Hospital, Conquest Hospital Dr. Sunil Gupta, Dr. Simon Weston-Smith, Dr. 
Satyajit Sahu 
14 
Salford Royal Hospital Dr. Simon Jowitt 14 
Torbay Hospital, Torquay Dr. Heather Eve, Dr. Deborah Turner 14 
Countess of Chester Hospital Dr. Gillian Brearton, Dr. Salah Tueger 13 
Monklands Hospital, Hairmyres Hospital, Wishaw General Hospital Dr. Iain Singer 13 
Pinderfields General Hospital Wakefield, Dewsbury & District 
Hospital, Pontefract Hospital 
Dr. John Ashcroft 13 
Poole Hospital Dr. Ram Jayaprakash, Dr. Fergus Jacki 13 
Sunderland Royal Hospital Dr. Victoria Hervey, Dr. Scott Marshall, Dr. Simon 
Lyons 
13 
Wythenshawe Hospital, Manchester Dr. Simon Watt 13 
Borders General Hospital, Melrose Dr. Jenny Buxton, Dr. Srivnivasa Dasari, Dr. John 
Tucker, Dr. Ashok Okhandiar 
12 
Hereford County Hospital Dr. Lisa Robinson 12 
Maidstone Hospital, Tunbridge Wells Hospital Dr. Don Gillett, Dr. Lalita Banerjee 12 
Royal Liverpool Hospital Dr. Stephen Hawkins, Prof. Patrick Chu 12 
Rotherham General Hospital Dr. Richard Went, Dr. Helen Barker 11 
Royal Bolton Hospital Dr. Chetan Patalappa, Dr. Suzanne Roberts, Dr. 
Mark Grey, Dr. Claire Barnes 
11 
Bradford Royal Infirmary Dr. Sam Ackroyd 10 
George Eliot Hospital, Nuneaton Dr. Mekkali Narayanan 10 
Nevill Hall Hospital, Abergavenny Dr. Nilima Parry-Jones 10 
North Devon District Hospital, Barnstaple Dr. Paul Kerr, Dr. Malcolm Hamilton 10 
St Helens Hospital, Whiston Hospital Dr. Toby Nicholson 10 
University Hospital Aintree Dr. Lynny Yung, Dr. Barbara Hammer 10 
Scunthorpe General Hospital Dr. Sanjeev Jalihal 9 
Warwick Hospital Dr. Carolina Arbuthnot 9 
Glan Clwyd Hospital, Rhyl Dr. Earnest Hartin, Dr. Christina Hoyle 7 
James Paget Hospital, Great Yarmouth Dr. Cesar Gomez, Dr. Shalal Sadullah 7 
Arrowe Park, Wirral Dr. Ranjit Dasgupta, Dr. Nauman Butt 5 
Darent Valley Hospital Dr. Tariq Shafi, Dr. Anil Kamat 4 
Ysbyty Gwynedd, Bangor Dr. Sally Evans, Dr. Melinda Hamilton, Dr. David 
Edwards 
4 
Addenbrookes Hospital, Cambridge Dr. Jenny Craig, Dr. Charles Crawley 3 
Royal Alexandra Hospital, Paisley Dr. Alison McCaig, Dr. Alison Sefcick 2 
 
